Pharmacokinetics and pharmacodynamics of repeat dosing of gabapentin in adult horses

被引:2
作者
Gold, Jenifer R. [1 ]
Grubb, Tamera L. [1 ]
Cox, Sherry [2 ]
Malavasi, Lais [1 ]
Villarino, Nicholas L. [1 ]
机构
[1] Washington State Univ, Dept Vet Clin Sci, 100 Grimes Way,ABDF 1020, Pullman, WA 99164 USA
[2] Univ Tennessee, Dept Biomed & Diagnost Sci, Knoxville, TN USA
关键词
analgesia; equine; neuropathic pain; plasma disposition; safety; ORALLY-ADMINISTERED GABAPENTIN; POSTOPERATIVE PAIN; DOGS;
D O I
10.1111/jvim.16386
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background The repeated administration of high doses of gabapentin may provide better analgesia in horses than current clinical protocols. Hypothesis and Objectives Administration of gabapentin at 40 and 120 mg/kg PO q 12 h for 14 days will not alter serum biochemistry findings or cause adverse effects. Our objectives were to evaluate the effect of gabapentin on serum biochemistry, physical examination, and plasma pharmacokinetics of gabapentin. Animals Six healthy adult mares. Methods Horses received 40 and 120 mg/kg of gabapentin orally q 12 h for 14 days. Horses were examined and scored for ataxia and sedation daily. Serum biochemistry variables were analyzed before treatment and days 7 and 14 after gabapentin administration. Plasma disposition of gabapentin was evaluated after the first and last drug administration. Pharmacokinetic parameters were estimated using noncompartmental analysis. Results No changes occurred in physiologic or biochemical variables. Median (range) maximal plasma gabapentin concentrations (mu g/mL) after the last dose (day 15) were 7.6 (6.2-11) and 22 (14-33) for 40 mg/kg and 120 mg/kg doses respectively. Maximal concentration of gabapentin was reached within 1 hour after drug administration. Repeated administration of gabapentin resulted in a median (range) area under the curve (AUC(0-12 hours)) last/first dose ratio of 1.5 (1.00-2.63) and 2.92 (1.4-3.8) for the 40 and 120 mg/kg regimens, respectively. Conclusion and Clinical Importance Our results suggest that horses tolerate gabapentin up to 120 mg/kg PO q 12 h for 14 days. The analgesic effect of the dosage regimens evaluated in our study warrants further research.
引用
收藏
页码:792 / 797
页数:6
相关论文
共 50 条
  • [41] Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
    Zhang, Libo
    Zhang, Weilong
    Xu, Yufeng
    Dong, Lihou
    Sun, Yunjuan
    Jia, Yingmin
    Li, Zhichuan
    Chen, Bo
    Hou, Jie
    Zhang, Jianzhong
    ADVANCES IN THERAPY, 2024, : 2953 - 2965
  • [42] Multidose misoprostol pharmacokinetics and its effect on the fecal microbiome in healthy, adult horses
    Pfeifle, Rachel L.
    Ericsson, Aaron C.
    McCoy, Annette M.
    Boothe, Dawn M.
    Wooldridge, Anne A.
    Groover, Erin S.
    -Rodriguez, Tamara Sierra
    Lascola, Kara M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2023, 84 (03)
  • [43] Evaluation of physical variables, thermal nociceptive threshold testing and pharmacokinetics during placement of transdermal buprenorphine matrix-type patch in healthy adult horses
    Paranjape, Vaidehi V.
    Knych, Heather K.
    Berghaus, Londa J.
    Cathcart, Jessica
    Giancola, Shyla
    Craig, Hannah
    James, Caroline
    Saksena, Siddharth
    Reed, Rachel A.
    FRONTIERS IN PAIN RESEARCH, 2024, 5
  • [44] Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase
    Piechowski-Jozwiak, Bartlomiej
    Abidi, Emna
    El Nekidy, Wasim S.
    Bogousslavsky, Julien
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (02) : 165 - 176
  • [45] Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
    Appeldoorn, T. Y. J.
    Munnink, T. H. Oude
    Morsink, L. M.
    Lub-de Hooge, M. N.
    Touw, D. J.
    CLINICAL PHARMACOKINETICS, 2023, 62 (04) : 559 - 571
  • [46] Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat
    Kamel, Bishoy
    Graham, Garry G.
    Williams, Kenneth M.
    Pile, Kevin D.
    Day, Richard O.
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 459 - 475
  • [47] Voriconazole Pharmacokinetics and Pharmacodynamics in Children
    Neely, Michael
    Rushing, Teresa
    Kovacs, Andrea
    Jelliffe, Roger
    Hoffman, Jill
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (01) : 27 - 36
  • [48] Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin
    Molina, Kyle C.
    Miller, Matthew A.
    Mueller, Scott W.
    Van Matre, Edward T.
    Krsak, Martin
    Kiser, Tyree H.
    CLINICAL PHARMACOKINETICS, 2022, 61 (03) : 363 - 374
  • [49] Pharmacokinetics and pharmacodynamics of inhaled corticosteroids
    Derendorf, H
    Hochhaus, G
    Meibohm, B
    Möllmann, H
    Barth, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) : S440 - S446
  • [50] Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline
    McCarthy, Matthew W.
    CLINICAL PHARMACOKINETICS, 2019, 58 (09) : 1149 - 1153